Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (3) Autor Barros,Marcelo Viana de Lima (1) Campos,Silvia V (1) Ceriotto,Mariana (1) Dalben,Mirian (1) Ferraiuoli,Giovanna Ianini (1) Freitas,Angela C (1) Hadlich,Marcelo (1) Hernandez,Adrian V (1) João,Esaú Custodio (1) Kreitchmann,Regis (1) Lima,Ana Beatriz Ribeiro (1) Lorenzo,Andrea Rocha de (1) Meirelles,Vanderson (1) Melo,Victor Hugo (1) Mussi-Pinhata,Marisa Márcia (1) Peixoto,Mario Ferreira (1) Pilotto,José Henrique (1) Read,Jennifer (1) Song,Alice TW (1) Souza,Ricardo da Silva de (1) Mais... Palavra-chave HIV protease inhibitors (3) HIV (2) Acquired immunodeficiency syndrome (1) Antiretroviral therapy (1) Brazil (1) Cardiovascular diseases (1) Coronary artery disease (1) Drug toxicity (1) Highly active (1) Pregnancy (1) Mais... Tipo do documento Info:eu-repo/semantics/article (3) Ano 2011 (3) País Brazil (3) Idioma Inglês (3)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 3 Primeira ... 1 ... Última Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities BJID Peixoto,Mario Ferreira; Pilotto,José Henrique; Stoszek,Sonia Karolina; Kreitchmann,Regis; Mussi-Pinhata,Marisa Márcia; Melo,Victor Hugo; João,Esaú Custodio; Ceriotto,Mariana; Souza,Ricardo da Silva de; Read,Jennifer. OBJECTIVES: To describe laboratory abnormalities among HIV-infected women and their infants with standard and increased lopinavir/ritonavir (LPV/r) dosing during the third trimester of pregnancy. METHODS: We evaluated data on pregnant women from NISDI cohorts (2002-2009) enrolled in Brazil, who received at least 28 days of LPV/r during the third pregnancy trimester and gave birth to singleton infants. RESULTS: 164 women received LPV/r standard dosing [(798/198 or 800/200 mg/day) (Group 1)] and 70 increased dosing [(> 800/200 mg/day) (Group 2)]. Group 1 was more likely to have advanced clinical disease and to use ARVs for treatment, and less likely to have CD4 counts > 500 cells/mm³. Mean plasma viral load was higher in Group 2. There were... Tipo: Info:eu-repo/semantics/article Palavras-chave: Pregnancy; HIV; HIV protease inhibitors; Drug toxicity. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000300013 Prevalence and factors associated with darunavir resistance mutations in multi-experienced HIV-1-infected patients failing other protease inhibitors in a referral teaching center in Brazil BJID Vidal,Jose E; Freitas,Angela C; Song,Alice TW; Campos,Silvia V; Dalben,Mirian; Hernandez,Adrian V. Information about resistance profile of darunavir (DRV) is scarce in Brazil. Our objectives were to estimate the prevalence of DRV resistance mutations in patients failing protease inhibitors (PI) and to identify factors associated with having more DRV resistance mutations. All HIV-infected patients failing PI-based regimens with genotyping performed between 2007 and 2008 in a referral teaching center in São Paulo, Brazil, were included. DRV-specific resistance mutations listed by December 2008 IAS-USA panel update were considered. Two Poisson regression models were constructed to assess factors related to the presence of more DRV resistance mutations. A total of 171 HIV-infected patients with available genotyping were included. The number of patients with... Tipo: Info:eu-repo/semantics/article Palavras-chave: Antiretroviral therapy; Highly active; HIV protease inhibitors; Acquired immunodeficiency syndrome; Brazil. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000300011 Risk of coronary artery disease in individuals infected with human immunodeficiency virus BJID Vilela,Felippe Dantas; Lorenzo,Andrea Rocha de; Tura,Bernardo Rangel; Ferraiuoli,Giovanna Ianini; Hadlich,Marcelo; Barros,Marcelo Viana de Lima; Lima,Ana Beatriz Ribeiro; Meirelles,Vanderson. Current treatment for human immunodeficiency virus (HIV) infection has improved survival and allowed infected patients to develop atherosclerotic coronary artery disease (CAD). Specific strategies to reduce cardiovascular risk in the infected population have not been developed. It is necessary to know the magnitude of cardiovascular risk in this population. OBJECTIVES: This study aimed to assess cardiovascular risk using a well-known clinical score and to investigate coronary artery calcium scoring (CACS) in this population. METHODS: This was a cross-sectional study. Adults with HIV infection were studied. Demographic, clinical and anthropometric data, serum glucose and lipids were obtained. Cardiovascular risk was calculated through Framingham risk score... Tipo: Info:eu-repo/semantics/article Palavras-chave: Coronary artery disease; HIV; Cardiovascular diseases; HIV protease inhibitors. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000600004 Registros recuperados: 3 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco